BioCryst Pharmaceuticals, Inc. (BCRX)

5,18 -0,08 (-1,43%) A partir del 12:16PM EDT. Mercado abierto.

BioCryst Pharmaceuticals, Inc.

4505 Emperor Boulevard
Suite 200
Durham, NC 27703
United States
919 859 1302
https://www.biocryst.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 536

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Jon P. Stonehouse	CEO, President & Executive Director	1,23M	647,14k	1961
Mr. Anthony J. Doyle	Senior VP, CFO & Interim Principal Accounting Officer	845,93k	N/A	1980
Ms. Alane P. Barnes	Senior VP, Chief Legal Officer & Corporate Secretary	794,75k	N/A	1966
Dr. Helen M. Thackray FAAP, M.D.	Chief Research & Development Officer	976,15k	N/A	1968
Mr. Charles K. Gayer	Senior VP & Chief Commercial Officer	794,12k	N/A	1971
Mr. John D. Bluth	Chief Communications Officer	N/A	N/A	1973
Ms. Stephanie Angelini	Chief People Officer	N/A	N/A	N/A
Dr. William P. Sheridan MBBS	Chief Development Officer	784,09k	4,4M	1955
Dr. Yarlagadda S. Babu Ph.D.	Chief Discovery Officer	691,45k	1,25M	1953
Ms. Jinky Ang Rosselli	Chief Data & Insights Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Gobierno corporativo

El ISS Governance QualityScore de BioCryst Pharmaceuticals, Inc., a día 1 de mayo de 2024, es 6. Las puntuaciones base son Auditoría: 8; Tablero: 3; Derechos de los accionistas: 8; Compensación: 5.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.